Psoriasishttps://en.wikipedia.org/wiki/Psoriasis
Psoriasis minangka penyakit autoimun sing kronis lan ora nular, ditandai dening area kulit sing ora normal. Wilayah kasebut abang utawa ungu ing sawetara wong, lan kulit dadi luwih peteng, garing, gatel, lan bersisik. Cedera ing kulit bisa nyebabake owah‑owahan kulit psoriatik ing titik kasebut, sing dikenal minangka “fenomena Koebner”.

Macam‑macam perawatan bisa mbantu ngontrol gejala. Pangobatan kalebu krim steroid, krim vitamin D3, sinar ultraviolet, lan obat imunosupresif kayata methotrexate. Udakara 75 % kasus sing melibatkan kulit bisa diatasi mung nganggo krim. Macam‑macam agen imunologi biologis wis dikembangake kanggo perawatan psoriasis.

Psoriasis minangka kelainan umum sing mengaruhi 2‑4 % populasi. Pria lan wanita kena pengaruh kanthi frekuensi sing padha. Penyakit iki bisa muncul ing umur apa wae, nanging biasane diwiwiti nalika dewasa. Artritis psoriatik mengaruhi nganti 30 % individu kanthi psoriasis.

○ Pengobatan – Obat OTC
Cahaya matahari bisa mbantu psoriasis amarga nyebabake perubahan imunologis ing pasien. Salep hidrokortison ringan bisa mbantu ngobati lesi cilik psoriasis.
#OTC steroid ointment

○ Pengobatan
Psoriasis minangka penyakit kronis lan akeh agen perawatan sing diteliti. Obat biologis paling efektif nanging sangat mahal.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)
☆ AI Dermatology — Free Service
Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
  • Punggung lan lengen wong sing nandhang psoriasis
  • Psoriasis khas
  • Guttate Psoriasis: Asring kedadeyan sawisé gejala kadhemen.
  • Guttate Psoriasis
  • Plak bersisik sing kandel lan eritema minangka manifestasi khas psoriasis.
  • Psoriasis ing telapak tangan. Yen ana ing telapak tangan, lepuh bisa muncul.
  • Psoriasis pustular parah.
  • Guttate Psoriasis
References Psoriasis 28846344 
NIH
 Phototherapy 33085287 
NIH
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).